SHERP

Developing a multi-center clinical data mart of ACEI and ARB for real-world evidence (RWE)

DC Field Value Language
dc.contributor.authorKim, Hun-Sung-
dc.contributor.authorLee, Sue Hyun-
dc.contributor.authorKim, Tong Min-
dc.contributor.authorKim, Ju Han-
dc.date.accessioned2019-03-12T05:18:39Z-
dc.date.available2019-03-12T14:23:35Z-
dc.date.issued2018-12-15-
dc.identifier.citationClinical Hypertension, 24(1):18ko_KR
dc.identifier.issn2056-5909-
dc.identifier.urihttp://hdl.handle.net/10371/146990-
dc.description.abstractBackground
Randomized controlled trials can be expensive and time-consuming, leading to medical researchers utilizing real-world evidence (RWE) based on already-collected data. We aimed to conduct various RWE studies on angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blocker (ARB), commonly used as first-line therapy for blood pressure, and to develop a multi-center clinical data mart (CDM) of ACEI/ARB for various clinical purposes.

Methods
Data from electronic medical records of St. Mary’s Hospital and the Seoul National University Hospital were collected. We obtained blood and urine test results of patients within the 30 days prior to their first prescription of ACEI or ARB, as well as the first date of diagnosis and presence of various chronic and cardiovascular diseases using the International Classification of Diseases-10 classification. One researcher managed data quality and collation for each hospital in order to facilitate patient anonymity. When results were unclear, the responsible investigator for each hospital attempted to resolve ambiguities by direct chart review.

Results
A total of 102,333 patients who were prescribed ACEI or ARB for the first time were included (21,481 ACEI, 80,551 ARB, and 301 both). Our ACEI/ARB-CDM included short-term studies (within 12 months) to observe changes in various blood or urinary laboratory test values after the initial prescription of ACEI or ARB and long-term studies to confirm the incidence of various diseases.

Conclusion
We established a CDM of RWE for ACEI/ARB prescription, which included various clinical studies. As we accumulate experience in this process, we expect that the use of RWE research will grow and develop.
ko_KR
dc.description.sponsorshipThe research was supported by funding from the Korean Society of Hypertension (2018).ko_KR
dc.language.isoenko_KR
dc.publisherBioMed Centralko_KR
dc.subjectAngiotensin-converting enzyme inhibitors (ACEI)ko_KR
dc.subjectAngiotensin II receptor blocker (ARB)ko_KR
dc.subjectClinical data mart (CDM)ko_KR
dc.subjectReal world data (RWD)ko_KR
dc.subjectReal world evidence (RWE)ko_KR
dc.titleDeveloping a multi-center clinical data mart of ACEI and ARB for real-world evidence (RWE)ko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김훈성-
dc.contributor.AlternativeAuthor이수현-
dc.contributor.AlternativeAuthor김통민-
dc.contributor.AlternativeAuthor김주한-
dc.identifier.doi10.1186/s40885-018-0103-7-
dc.language.rfc3066en-
dc.rights.holderThe Author(s).-
dc.date.updated2018-12-16T04:15:24Z-
Appears in Collections:
College of Natural Sciences (자연과학대학)Program in Bioinformatics (협동과정-생물정보학전공)Journal Papers (저널논문_협동과정-생물정보학전공)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse